Articles tagged with “rmc-6236”

Daraxonrasib RAS(ON) Inhibitor: Pancreatic Cancer Results

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

40 min read

4/28/2026

daraxonrasib rmc-6236 pancreatic cancer ras(on) inhibitors kras mutations rasolute-302 targeted therapy oncology clinical trials